C Heidbreder, PJ Fudala, MK Greenwald - Drug and alcohol dependence …, 2023 - Elsevier
Buprenorphine-based medications were first approved by the United States Food and Drug Administration in 2002 for the treatment of opioid dependence, or opioid use disorder (OUD) …
A Spadaro, A Sarker, W Hogg-Bremer, JS Love… - Clinical …, 2022 - Taylor & Francis
Background Induction of buprenorphine, an evidence-based treatment for opioid use disorder (OUD), has been reported to be difficult for people with heavy use of fentanyl, the …
MK Greenwald, AA Herring, J Perrone… - Annals of Emergency …, 2022 - Elsevier
Buprenorphine induction for treating opioid use disorder is being implemented in emergency care. During this era of high-potency synthetic opioid use, novel and divergent …
D Button, J Hartley, J Robbins… - Journal of addiction …, 2022 - journals.lww.com
Objectives: Patients with opioid use disorder (OUD) can initiate buprenorphine without requiring a withdrawal period through a low-dose (sometimes referred to as “micro …
KL Sue, S Cohen, J Tilley… - Journal of Addiction …, 2022 - journals.lww.com
With the worst opioid overdose death crisis in the United States history, urgent new approaches to assist people who use drugs onto medication for opioid use disorder are …
M Soyka - Frontiers in Pharmacology, 2021 - frontiersin.org
Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine, a partial agonist at the mu receptor, are first-line medications in opioid maintenance …
This paper is the forty-fourth consecutive installment of the annual anthological review of research concerning the endogenous opioid system, summarizing articles published during …
AN Edinoff, OH Fahmy, NJ Spillers, AR Zaheri… - Current Pain and …, 2023 - Springer
Abstract Purpose of Review Opioid use disorder (OUD) is a chronic disorder in which a person loses control over the use of opioids, develops a compulsive behavior, and defends …
LW Suen, TG Lee, M Silva, P Walton… - Journal of addiction …, 2022 - journals.lww.com
Objectives Fear and risk of precipitated withdrawal are barriers for initiating buprenorphine in individuals with opioid use disorder, particularly among those using fentanyl. A …